

# Mass Spectrometric Quantitation of Nicotine, Cotinine, and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol in Human Toenails

Irina Stepanov,<sup>1</sup> Rachel Feuer,<sup>2</sup> Joni Jensen,<sup>2</sup> Dorothy Hatsukami,<sup>2</sup> and Stephen S. Hecht<sup>1</sup>

<sup>1</sup>The Cancer Center, University of Minnesota; <sup>2</sup>Transdisciplinary Tobacco Use Research Center, Minneapolis, Minnesota

## Abstract

Numerous studies have quantified total cotinine (the sum of cotinine and cotinine-*N*-glucuronide) and total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL; the sum of NNAL and its *O*- and *N*-glucuronides (NNAL-Glucs)] in the urine and blood of smokers, smokeless tobacco users, and nonsmokers exposed to environmental tobacco smoke. Analysis of hair and nails has several advantages over blood and urine testing, such as accumulation of xenobiotics during long-term exposure, ease of collection, and indefinite stability of samples. We developed sensitive methods for quantitation of nicotine, cotinine, and NNAL in human toenails. Nicotine and cotinine were analyzed by gas chromatography-mass spectrometry-selected ion monitoring. NNAL was assayed using liquid chromatography-electrospray ionization-tandem mass spectrometry-selected

reaction monitoring. The detection limits of the methods were 0.01 ng/mg toenail for nicotine, 0.012 ng/mg toenail for cotinine, and 0.02 pg/mg toenail for NNAL. In 35 smokers, the mean nicotine level was  $5.9 \pm 5.6$  ng/mg toenail, mean cotinine was  $1.6 \pm 1.3$  ng/mg toenail, and mean NNAL was  $0.41 \pm 0.67$  pg/mg toenail. Samples collected from six nonsmokers were negative for NNAL. In smokers, NNAL correlated with cotinine ( $r = 0.77$ ;  $P < 0.0001$ ). The results of this study for the first time show the presence of cotinine and NNAL in human toenails. These sensitive and quantitative methods should be useful in epidemiologic studies of the role of chronic tobacco smoke exposure, including environmental tobacco smoke exposure, in human cancer. (Cancer Epidemiol Biomarkers Prev 2006; 15(12):2378–83)

## Introduction

Cigarette smoking is a major cause of cancer deaths worldwide and also causes vascular and respiratory diseases (1). Nicotine and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) are two important tobacco smoke constituents representing its critical biological properties. Nicotine is the major tobacco alkaloid and the main known addictive component of tobacco smoke. NNK is a highly effective lung carcinogen in rats and also causes lung tumors in mice and hamsters (2). It also produces tumors of the pancreas, liver, and nasal mucosa (2), and administration together with another tobacco-specific nitrosamine *N*'-nitrosornicotine caused tumors of the oral cavity in rats (3). NNK and *N*'-nitrosornicotine have been classified recently by the IARC as carcinogenic to humans (group 1; ref. 4).

Biomarkers of tobacco smoke exposure are crucial in understanding mechanisms by which tobacco products cause cancer. Nicotine is rapidly metabolized in the human body, about 70% to 80% of the dose being converted to cotinine (5). Measurements of nicotine and cotinine levels in urine, saliva, and blood are commonly used to monitor systemic exposure to cigarette smoke in smokers and nonsmokers exposed to environmental tobacco smoke (ETS; refs. 6–9). Urinary metabolites of NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronides (NNAL-Glucs), are excellent biomarkers of NNK uptake in rodents and humans (10, 11). Numerous studies have quantified total NNAL, the sum of NNAL and NNAL-Glucs, in the urine of smokers, smokeless

tobacco users, and nonsmokers exposed to ETS (11–16). Total NNAL has also been quantified in the blood of smokers and smokeless tobacco users (15, 16), and a practical and sensitive method for total NNAL quantitation in plasma has been developed recently (17).

Analysis of keratinic matrices, such as hair and nails, has several advantages over urine, blood, and saliva testing. Thus, growth rates are  $\sim 1$  cm monthly for hair (18),  $\sim 0.3$  cm monthly for fingernails, and  $\sim 0.1$  cm monthly for toenails (19); therefore, biomarker levels in hair and nails reflect exposure over a longer period. Other advantages include relative ease of sample collection and storage and seemingly indefinite stability of the collected sample caused by incorporation of the analytes of interest into the keratinic matrix (19). In recent years, hair was most commonly used for analysis of drugs of abuse for forensic purposes (19–21). Hair analysis has also been widely used to assess fetal exposure to nicotine through maternal smoking during pregnancy (21–23) and childhood exposure to ETS (18, 24, 25). Fingernails and toenails have been used for the detection of drugs of abuse (26) and in studies of arsenic intoxication (27, 28), occupational exposures (29, 30), and environmental exposure of children to trace elements (31–33). Unlike hair, nails grow in two directions, length and thickness, thus leading to dual mechanisms of xenobiotic incorporation, via the nail matrix and nail bed (19, 34). Due to the contribution of the nail bed to the incorporation process, the content of analytes in nail clippings reflects cumulative exposure over a relatively long period (19). Thus, nails seem to be more suitable in studies of chronic exposure, whereas hair is useful in monitoring of exposure during discrete periods by the axial distribution of analytes. Toenails grow more slowly than fingernails and are less likely to be environmentally contaminated with the analyte of interest than fingernails or hair (19).

It is biologically plausible that cotinine and NNAL are present in human toenails and could serve as biomarkers of chronic human exposure to nicotine and NNK. Verghese et al.

Received 4/6/06; revised 9/25/06; accepted 10/10/06.


**Grant support:** National Cancer Institute.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Irina Stepanov, The Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street Southeast, Minneapolis, MN 55455. Phone: 612-624-4998; Fax: 612-626-5135. E-mail: stepa011@umn.edu

Copyright © 2006 American Association for Cancer Research.

doi:10.1158/1055-9965.EPI-06-0265



**Figure 1.** Structures of compounds analyzed in human toenails.

(35) reported an interesting physical sign related to smoking cessation, which they termed "harlequin nail." They observed a distinct demarcation line in toenails of patients showing when they had stopped smoking. In a recent study, Al-Delaimy et al. (36) quantified nicotine in toenails using high-performance liquid chromatography (HPLC) with electrochemical detection. It was found that toenail nicotine levels differ significantly according to tobacco smoke exposure, being ~6-fold higher in smokers compared with nonsmokers exposed to ETS. In his study, Al-Delaimy et al. used toenail clippings collected as a part of the Nurses' Health Study, which was established in 1976 and involved 121,700 U.S. female registered nurses. The same study provided toenail clippings for investigation of toenail selenium concentrations and bladder cancer risk (37). Toenail clippings are often collected and stored in large-scale epidemiologic studies and could be used for investigations of tobacco smoke constituent uptake and development of cancer later in life.

The purpose of our study was to develop sensitive methods for quantitation of cotinine and NNAL in human toenails. Because HPLC with electrochemical detection is not as specific as mass spectrometry (MS), we developed a gas chromatography-MS (GC-MS) method for quantitation of nicotine and cotinine in toenails. NNAL was quantified by liquid chromatography-electrospray ionization-tandem MS (LC-ESI-MS/MS). Structures of the biomarkers analyzed here are shown in Fig. 1.


## Materials and Methods

**Caution.** NNAL is carcinogenic and mutagenic and should be handled with extreme care, using appropriate protective clothing and ventilation at all times.

**Chemicals and Enzymes.** NNAL was purchased from Toronto Research Chemicals, Inc. (Toronto, Ontario, Canada). [Pyridine-D<sub>4</sub>]NNAL was synthesized from [pyridine-D<sub>4</sub>]ethyl nicotinate (Cambridge Isotope Laboratories, Cambridge, MA) as described previously (38, 39). [<sup>13</sup>C<sub>6</sub>]NNAL was synthesized by NaBH<sub>4</sub> reduction of [<sup>13</sup>C<sub>6</sub>]NNK (Cambridge Isotope Laboratories). Nicotine, [CD<sub>3</sub>]nicotine, cotinine, [CD<sub>3</sub>]cotinine, and β-glucuronidase (type IX-A from *Escherichia coli*) were purchased from Sigma Chemical Co. (St. Louis, MO).

**Apparatus.** Analysis of nicotine and cotinine by GC-MS-selected ion monitoring was carried out with a model 6890 GC equipped with an autosampler and interfaced with a model 5973 mass-selective detector (Agilent Technologies, Palo Alto, CA) as described previously (40, 41).

LC-ESI-MS/MS was carried out on a Finnigan TSQ Quantum Discovery Max instrument (Thermo Electron Corp., Waltham, MA) interfaced with an Agilent model 1100 capillary HPLC system and a model 1100 micro autosampler (Agilent Technologies) by using a slight modification of a method described previously (17). The HPLC was fitted with a 150 × 0.5 mm ZORBAX SB C18 RR 3.5-μm column (Agilent Technologies) eluted in isocratic mode with 35% methanol in H<sub>2</sub>O for 15 min at a flow rate of 10 μL/min. The column was maintained at 25°C. MS/MS variables were as follows: positive ion electrospray mode with selected reaction monitoring for *m/z* 210 → 180 for NNAL, *m/z* 214 → 184 for [pyridine-D<sub>4</sub>]NNAL, and *m/z* 216 → 186 for [<sup>13</sup>C<sub>6</sub>]NNAL, at 1.0 a.m.u. scan width. The collision gas was Ar at a pressure of 1 mTorr, with collision energy of 12 eV. The quadrupoles were operated at a resolution of 0.7 a.m.u.



**Figure 2.** Analytic procedure for nicotine, cotinine, and NNAL analysis in human toenails.

**Table 1. Nicotine and cotinine in subjects with different exposures**

Group	No. subjects*	Mean nicotine (ng/mg)	Mean cotinine (ng/mg)
Nonsmokers, not exposed to ETS	4	0.11	0.012
Nonsmokers, exposed to ETS	2	0.37	0.036
Smokers	2	1.2	0.33

\*Samples from each subject were analyzed in duplicate.

**Subjects.** Thirty-five active smokers were recruited from a longitudinal study of tobacco biomarkers and several smoking cessation studies conducted at the Transdisciplinary Tobacco Use Research Center (Minneapolis, MN). The entrance criteria of these studies required subjects to smoke at least 10 cigarettes daily for at least 1 year. Subjects were offered the opportunity to participate in this addendum study for additional payment. All studies were approved by the University of Minnesota Research Subjects' Protection Programs Institutional Review Board Human Subjects Committee.

**Analyses.** Toenail clippings (20-30 mg for nicotine/cotinine assay and 50-80 mg for NNAL assay) were weighed into 5-mL polypropylene tubes and washed without agitation for 1.5 to 2 h in 2 mL  $\text{CH}_2\text{Cl}_2$  at room temperature. Then, the tubes were vortexed,  $\text{CH}_2\text{Cl}_2$  was removed by aspiration, and the toenails were vortexed one more time with 1 mL  $\text{CH}_2\text{Cl}_2$ . After washing, the toenails were dried in a heating block at 50°C (5-10 min).

**Nicotine and Cotinine Analysis.** To analyze nicotine and cotinine, toenails were digested at 50°C overnight in 0.5 mL 1 N NaOH. The next day, 5  $\mu\text{L}$  of a mixture containing 5 ng/ $\mu\text{L}$  each of  $[\text{CD}_3]$ nicotine and  $[\text{CD}_3]$ cotinine as internal standards were added to a 5-mL glass centrifuge tube (Kimble, Vineland, NJ) containing 0.5 mL of 25% aqueous  $\text{K}_2\text{CO}_3$  and 1 mL  $\text{CH}_2\text{Cl}_2$ . The digested toenail sample was added to the tube, and the mixture was treated and analyzed as described previously (40, 41).

**NNAL Analysis.** To analyze NNAL, toenails were digested at 50°C overnight in 1 mL 1 N NaOH. The next day, the digests were added to a 15-mL glass centrifuge tube containing 10 pg  $[\text{pyridine-D}_4]$ NNAL as internal standard in 4 mL potassium phosphate buffer (prepared from 0.1 mol/L  $\text{KH}_2\text{PO}_4$  adjusted

to pH 7). The mixture was applied to a 5-mL ChemElut cartridge (Varian, Harbor City, CA) and eluted with  $2 \times 8$  mL  $\text{CH}_2\text{Cl}_2$  into a 15-mL glass centrifuge tube. The combined eluants were concentrated to dryness (Speedvac concentrator). The dry residue was redissolved in 1 mL  $\text{H}_2\text{O}$ , adjusted to pH 2 to 3, further purified on Oasis MCX cartridges (Waters Corp., Milford, MA), and transferred to autosampler vials as described previously (12). Dry samples were stored at -20°C. Before analysis by LC-ESI-MS/MS, samples were redissolved in 10  $\mu\text{L}$  of 2% methanol in  $\text{H}_2\text{O}$  containing 2.5 pg/ $\mu\text{L}$   $^{13}\text{C}_6$ NNAL as injection standard, and 5  $\mu\text{L}$  were injected.

**Statistical Analyses.** Pearson product moment correlation coefficients and statistical significance of the correlations were determined using SigmaPlot 2001, version 7.101 (SPSS, Inc., Chicago, IL).


## Results

The procedures for nicotine, cotinine, and NNAL analysis in toenails are summarized in the scheme shown in Fig. 2.


**Nicotine and Cotinine Assay.** We initially analyzed only a few samples collected from nonsmokers not exposed to ETS, two nonsmokers exposed to ETS, and two smokers. The results of this first experiment summarized in Table 1 were in good agreement with the results reported by Al-Delaimy et al. (36) in terms of nicotine levels in different exposure categories. A typical GC-MS chromatogram of cotinine in human toenails is shown in Fig. 3.

Precision of the developed nicotine and cotinine assay was determined by dividing a toenail digest from a single smoker into six aliquots and analyzing each for nicotine and cotinine. Relative SDs were 10.1% for nicotine and 4.8% for cotinine. The accuracy of the assay was determined by spiking an ETS-exposed nonsmoker's toenail digest with 0.5, 1, 2.5, and 5 ng cotinine/mg toenail. Analysis gave 0.42, 0.84, 2.3, and 4.4 ng cotinine/mg toenail, respectively, producing good correlation between spiked and measured cotinine ( $r = 0.99$ ). The detection limits of the method were 0.01 ng/mg toenail for nicotine and 0.012 ng/mg toenail for cotinine.

**NNAL Assay.** The aqueous toenail digest was enriched by partitioning with  $\text{CH}_2\text{Cl}_2$  on a ChemElut liquid-liquid extraction cartridge (Fig. 2). Final enrichment was accomplished by a mixed mode cation exchange extraction on an Oasis MCX solid-phase extraction cartridge. The fraction



**Figure 3.** GC-MS chromatograms obtained on analysis of cotinine in toenails from a smoker. **A.** Cotinine,  $m/z$  176 (molecular ion) and  $m/z$  98 (used for quantitation). **B.**  $[\text{CD}_3]$ cotinine (internal standard),  $m/z$  179 (molecular ion), and  $m/z$  101 (used for quantitation).




**Figure 4.** Chromatograms obtained on LC-ESI-MS/MS analysis of NNAL, [pyridine-D<sub>4</sub>]NNAL (internal standard), and [<sup>13</sup>C<sub>6</sub>]NNAL (injection standard). **A.** standard mix. **B.** a smoker's toenail sample.

containing NNAL was then directly analyzed by LC-ESI-MS/MS. A typical chromatogram is shown on Fig. 4.

The detection limit of the assay for NNAL in toenails from smokers was 0.02 pg/mg toenail, starting with a 50 mg sample. Precision of the assay was determined by analyzing six aliquots of a smoker's digested toenail sample. The results were  $1.4 \pm 0.16$  fmol NNAL/mg toenail (relative SD, 11.4%). NNAL in the toenails from the same smoker was also determined by a modified method, in which  $\beta$ -glucuronidase treatment (37°C, overnight) was added after digestion and pH adjustment to 6 to 7. This modification did not affect the measured NNAL. The accuracy of the assay was determined by spiking aliquots of pooled nonsmokers' toenail digest with 0.5, 1, 2, 5, and 10 pg NNAL. Analysis gave 0.51, 1.1, 2.0, 5.3, and 9.2 pg NNAL, respectively, producing high correlation ( $r = 0.99$ ) between spiked and measured NNAL. Recoveries of internal standard averaged  $22 \pm 10\%$  ( $n = 28$ ).

**Analysis of Toenail Samples from Smokers.** The assays were applied to toenail samples from 35 smokers and 6 nonsmokers. Data for nicotine, cotinine, and NNAL in toenails from smokers are summarized in Fig. 5. All nonsmoker samples were negative for NNAL; nicotine and cotinine levels in these subjects averaged 0.09 and 0.01 ng/mg, respectively.




**Figure 5.** Nicotine, cotinine, and NNAL in toenails of smokers. Boxes, 25th and 75th percentiles; lines outside boxes, 10th and 90th percentiles; dots, outliers.

In smokers, mean nicotine level was  $5.9 \pm 5.6$  ng/mg toenail, mean cotinine was  $1.6 \pm 1.3$  ng/mg toenail, and mean NNAL was  $0.41 \pm 0.67$  pg/mg toenail. NNAL correlated with cotinine ( $r = 0.77$ ;  $P < 0.0001$ ; Fig. 6).

## Discussion

We developed sensitive methods for quantitation of nicotine, cotinine, and NNAL in human toenails. Previous studies on cotinine and total NNAL in biological fluids, such as urine and blood, provided information on short-term exposure to nicotine and NNK. Thus, cotinine has a half-life of about 15 to 17 h, and the distribution half-life for urinary NNAL is 3 to 4 days. Toenail cotinine and NNAL levels integrate tobacco smoke exposure over a relatively long period, about 3 to 5 months, thus being potentially useful biomarkers in studies of the role of chronic tobacco smoke exposure in human cancer. For the purposes of this study, the measurements were carried out mainly in smokers; cotinine was also quantified in two nonsmokers exposed to ETS. The limit of detection of these assays reached into the femtomol range for nicotine and cotinine and subfemtomol range for NNAL.



**Figure 6.** Relationship between cotinine and NNAL in the toenails of 31 smokers ( $r = 0.77$ ;  $P < 0.0001$ ).

For nicotine and cotinine analysis in toenails, we used GC-MS-selected ion monitoring, which is characterized by high sensitivity and specificity. The method also allows using deuterium-labeled nicotine and cotinine as internal standards, providing high accuracy of nicotine and cotinine quantitation in toenails. Overall, our results are in good agreement with those reported by Al-Delaimy et al. (Table 1; ref. 36). Small sample sizes limit our ability to compare these two methods, and future studies are necessary to assess toenail nicotine and cotinine levels in different exposure categories.

The method for NNAL analysis in toenails (Fig. 4) consists of a few simple steps and resembles our recently published method for total NNAL analysis in blood (17). Isocratic elution of the LC column considerably reduced the time needed for LC-MS-ESI analysis of a single sample. This modification did not result in appearance of coeluting peaks, which would interfere with quantitation (Fig. 5). It is unknown whether NNAL-Gluc is present in toenails. NNAL-*N*-Gluc would be hydrolyzed to NNAL at the initial step of the procedure, when the toenails are digested in 1 N NaOH (42). NNAL-*O*-Gluc is not hydrolyzed to NNAL by base treatment (42), but it is converted to NNAL by treatment with  $\beta$ -glucuronidase (12, 17, 42). Overnight treatment with  $\beta$ -glucuronidase of a smoker's toenail digest adjusted to pH 6 to 7 did not alter the measured NNAL, thus indicating that there is no NNAL-*O*-Gluc present in toenails, or its amount is extremely low.

Although toenail nicotine levels were assessed previously (36) and nicotine and cotinine were analyzed in another keratinic matrix, hair (reviewed in ref. 43), no other study has reported the presence of cotinine and NNAL in toenails. To validate our new methods and investigate the relationship between the analytes, we analyzed toenail clippings collected from active smokers. The interindividual variability and the ranges of toenail nicotine and cotinine levels observed here are remarkably similar to those observed on hair analysis. Thus, Kintz (44) reported 0.91 to 38.27 ng nicotine/mg hair and 0.09 to 4.99 ng cotinine/mg hair in 56 smokers. In our study, nicotine ranged from 0.79 to 22.67 ng/mg toenail, and cotinine ranged from 0.23 to 6.38 ng/mg toenail. This similarity is not surprising because the growth of both hair and nail is slow, and nicotine and cotinine are brought into these keratinic matrices by similar mechanisms (through the blood circulation). However, in our opinion, toenail analysis has several advantages over hair testing for studies of chronic exposure. Toenails are considered to be relatively free of external contamination and grow more slowly than hair, and the content of biomarkers in nail clippings reflects cumulative rather than discrete exposure, thus eliminating the issue of irregular growth and nonuniform axial distribution of biomarkers present in hair. Moreover, the limit of detection of nicotine in toenails (0.01 ng/mg toenail) is lower than that reported for mass spectrometric analysis of nicotine in hair (0.24 ng/mg hair; ref. 45).

The ratio between cotinine and NNAL in smokers' toenails was found to be  $\sim 4,600$  and is similar to that observed in the urine of smokers (15). The correlation of toenail cotinine with toenail NNAL observed in this study was also similar to that reported for the urine of smokers ( $r = 0.68$ ; ref. 46) and ETS-exposed nonsmokers ( $r = 0.71$ ; ref. 14).

Although this study provides accurate and sensitive methods for nicotine, cotinine, and NNAL analysis in human toenails, additional studies, such as a longitudinal study in smokers and investigation of the kinetics of cotinine and NNAL disappearance from quitters' toenails, are necessary to validate toenail cotinine and NNAL as useful biomarkers of human chronic exposure to tobacco smoke.

In summary, the results of this study show for the first time that cotinine and NNAL are present in human toenails. The methods developed here should be useful in epidemiologic studies of the role of chronic tobacco smoke exposure, including ETS exposure, in human cancer.

## Acknowledgments

We thank Steven G. Carmella for valuable advice on development of method, Dr. Peter W. Villalta for help with MS techniques, and Bob Carlson for editorial assistance.

## References

- IARC. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 83. Lyon (France): IARC; 2004. p.59–94.
- Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific *N*-nitrosamines. *Chem Res Toxicol* 1998;11:559–603.
- Hecht SS, Rivenson A, Braley J, et al. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. *Cancer Res* 1986;46:4162–6.
- IARC. Smokeless tobacco and tobacco-specific nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 89. Lyon (France): IARC. In press 2006.
- Benowitz NL, Jacob P III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. *Clin Pharmacol Ther* 1994;56:483–93.
- Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. *Pharmacol Rev* 2005;57:79–115.
- DeLeon J, Diaz FJ, Rogers T, et al. Total cotinine in plasma: a stable biomarker for exposure to tobacco smoke. *J Clin Psychopharmacol* 2002;22:496–501.
- Jarvis MJ, Primatesta P, Erens B, et al. Measuring nicotine intake in population surveys: comparability of saliva cotinine and plasma cotinine estimates. *Nicotine Tob Res* 2003;5:349–55.
- Heinrich J, Hoelscher B, Seiwert M, et al. Nicotine and cotinine in adults' urine: the German environmental survey 1998. *J Expo Anal Environ Epidemiol* 2005;15:74–80.
- Hecht SS. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. *Nat Rev Cancer* 2003;3:733–44.
- Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. *Carcinogenesis* 2002;23:907–22.
- Carmella SG, Akerkar S, Richie JP, Jr., et al. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. *Cancer Epidemiol Biomarkers Prev* 1995;4:635–42.
- Anderson KE, Carmella SG, Ming Ye, et al. Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke in their homes. *J Natl Cancer Inst* 2001;93:378–81.
- Hecht SS, Ming Ye, Carmella SG, et al. Metabolites of a tobacco-specific lung carcinogen in the urine of elementary school-aged children. *Cancer Epidemiol Biomarkers Prev* 2001;10:1109–16.
- Hecht SS, Carmella SG, Chen M, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. *Cancer Res* 1999;59:590–96.
- Hecht SS, Carmella SG, Ye M, et al. Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. *Cancer Res* 2002;62:129–34.
- Carmella SG, Han S, Villalta PW, et al. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' blood. *Cancer Epidemiol Biomarkers Prev* 2005;14:11:2669–72.
- Mahoney GN, Al-Delaimy WK. Measurement of nicotine in hair by reversed-phase high-performance liquid chromatography with electrochemical detection. *J Chromatogr B Biomed Sci Appl* 2001;753:179–87.
- Palmeri A, Pichini S, Pacifici R, et al. Drugs in nails. Physiology, pharmacokinetics, and forensic toxicology. *Clin Pharmacokinet* 2000;38:95–110.
- Pepin G, Gaillard Y. Concordance between self-reported drug use and findings in hair about cocaine and heroin. *Forensic Sci Int* 1997;84:37–41.
- Klein J, Forman R, Eliopoulou C, et al. A method for simultaneous measurement of cocaine and nicotine in neonatal hair. *Ther Drug Monit* 1994;16:67–70.
- Jacqz-Aigrain E, Zhang D, Maillard G, et al. Maternal smoking during pregnancy and nicotine and cotinine concentrations in maternal and neonatal hair. *Br J Obstet Gynaecol* 2002;109:909–11.
- Chan D, Caprara D, Blanchette P, et al. Recent developments in meconium and hair testing methods for the confirmation of gestational exposures to alcohol and tobacco smoke. *Clin Biochem* 2004;37:429–38.
- Al-Delaimy WK, Crane J, Woodward A. Passive smoking in children: effect of avoidance strategies at home as measured by hair nicotine levels. *Arch Environ Health* 2001;56:117–22.
- Woodruff S, Conway T, Edwards C, et al. Acceptability and validity of hair collection from Latino children to assess exposure to environmental tobacco smoke. *Nicotine Tob Res* 2003;5:375–85.
- Pounds A, Pearson EF, Turner TD. Arsenic in fingernails. *J Forensic Sci* 1979;19:165–73.
- Engelhart DA, Jenkins AJ. Detection of cocaine analytes and opiates in nails from postmortem cases. *J Anal Toxicol* 2002;26:489–92.
- Kile ML, Houseman EA, Rodrigues E, et al. Toenail arsenic concentrations, GSTT1 gene polymorphisms, and arsenic exposure from drinking water. *Cancer Epidemiol Biomarkers Prev* 2005;14:10:2419–26.

29. Gerhardsson L, Englyst V, Lundstrom NG, et al. Lead in tissues of deceased lead smelter workers. *J Trace Elem Med Biol* 1995;9:136–43.
30. Morton J, Mason HJ, Ritchie KA, et al. Comparison of hair, nails, and urine for biological monitoring of low level inorganic mercury exposure in dental workers. *Biomarkers* 2004;9:47–55.
31. Wilhelm M, Hafner D, Lombeck I, et al. Monitoring of cadmium, copper, lead, and zinc status in young children using toenails: comparison with scalp hair. *Sci Total Environ* 1991;103:199–207.
32. Alexiou D, Koutselinis A, Manolidis C, et al. The content of trace elements (Cu, Zn, Fe, Mg) in fingernails of children. *Dermatologica* 1980;160:380–2.
33. Kasperk K, Iyengar GV, Feinendegen LE, et al. Multielement analysis of fingernail, scalp hair, and water samples from Egypt (a preliminary study). *Sci Total Environ* 1982;22:149–68.
34. Norton LA. Incorporation of thymidine-methyl- $H^3$  and glycine- $2H^3$  in the nail matrix and bed of humans. *J Invest Dermatol* 1971;56:61–8.
35. Verghese A, Krish G, Howe D, et al. The harlequin nail. A marker for smoking cessation. *Chest* 1990;97:236–8.
36. Al-Delaimy WK, Mahoney GN, Speizer FE, et al. Toenail nicotine levels as a biomarker of tobacco smoke exposure. *Cancer Epidemiol Biomarkers Prev* 2002;11:1400–4.
37. Michaud DS, De Vivo I, Morris JS, et al. Toenail selenium concentrations and bladder cancer risk in women and men. *Br J Cancer* 2005;93:804–6.
38. Hecht SS, Lin D, Castonguay A. Effects of  $\alpha$ -deuterium substitution on the mutagenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). *Carcinogenesis* 1983;4:305–10.
39. Hecht SS, Young R, Chen CB. Metabolism in the F344 rat of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. *Cancer Res* 1980;40:4144–50.
40. Hecht SS, Carmella SG, Chen M, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. *Cancer Res* 1999;59:590–6.
41. Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. *Cancer Epidemiol Biomarkers Prev* 2005;14:885–91.
42. Carmella SG, Le K, Upadhyaya P, Hecht SS. Analysis of N- and O-glucuronides of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. *Chem Res Toxicol* 2002;15:545–50.
43. Al-Delaimy WK. Hair as biomarker for exposure to tobacco smoke. *Tob Control* 2002;11:176–82.
44. Kintz P. Gas chromatographic analysis of nicotine and cotinine in hair. *J Chromatogr* 1992;580:347–53.
45. Marchei E, Durgbanshi A, Rossi S, et al. Determination of arecoline (areca nut alkaloid) and nicotine in hair by high-performance liquid chromatography/electrospray quadrupole mass spectrometry. *Rapid Commun Mass Spectrom* 2005;19:22:3416–8.
46. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194–210.